369 related articles for article (PubMed ID: 22722554)
1. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases.
Lakatos G; Hritz I; Varga MZ; Juhász M; Miheller P; Cierny G; Tulassay Z; Herszényi L
Dig Dis; 2012; 30(3):289-95. PubMed ID: 22722554
[TBL] [Abstract][Full Text] [Related]
2. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease.
Mäkitalo L; Rintamäki H; Tervahartiala T; Sorsa T; Kolho KL
Scand J Gastroenterol; 2012 Jul; 47(7):785-94. PubMed ID: 22519363
[TBL] [Abstract][Full Text] [Related]
3. Imbalance of tissue inhibitors of metalloproteinases (TIMP) - 1 and - 4 serum levels, in patients with inflammatory bowel disease.
Kapsoritakis AN; Kapsoritaki AI; Davidi IP; Lotis VD; Manolakis AC; Mylonis PI; Theodoridou AT; Germenis AE; Potamianos SP
BMC Gastroenterol; 2008 Nov; 8():55. PubMed ID: 19036126
[TBL] [Abstract][Full Text] [Related]
4. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
[TBL] [Abstract][Full Text] [Related]
5. Expression of matrix metalloproteinases in patients with Wegener's granulomatosis.
Bjerkeli V; Halvorsen B; Damås JK; Nordøy I; Yndestad A; Aukrust P; Frøland SS
Ann Rheum Dis; 2004 Dec; 63(12):1659-63. PubMed ID: 15547092
[TBL] [Abstract][Full Text] [Related]
6. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases and their tissue inhibitors (TIMPs) in Plasmodium falciparum malaria: serum levels of TIMP-1 are associated with disease severity.
Dietmann A; Helbok R; Lackner P; Issifou S; Lell B; Matsiegui PB; Reindl M; Schmutzhard E; Kremsner PG
J Infect Dis; 2008 Jun; 197(11):1614-20. PubMed ID: 18700258
[TBL] [Abstract][Full Text] [Related]
8. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis.
Fiedorczyk M; Klimiuk PA; Sierakowski S; Gindzienska-Sieskiewicz E; Chwiecko J
J Rheumatol; 2006 Aug; 33(8):1523-9. PubMed ID: 16881109
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
10. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
Vandooren B; Kruithof E; Yu DT; Rihl M; Gu J; De Rycke L; Van Den Bosch F; Veys EM; De Keyser F; Baeten D
Arthritis Rheum; 2004 Sep; 50(9):2942-53. PubMed ID: 15457463
[TBL] [Abstract][Full Text] [Related]
11. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
Ciećko-Michalska I; Fedak D; Mach T
Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
[TBL] [Abstract][Full Text] [Related]
12. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease.
Koutroubakis IE; Xidakis C; Karmiris K; Sfiridaki A; Kandidaki E; Kouroumalis EA
Eur J Clin Invest; 2006 Feb; 36(2):127-32. PubMed ID: 16436095
[TBL] [Abstract][Full Text] [Related]
13. Expression of matrix metalloproteinases and their tissue inhibitors in the serum and cerebrospinal fluid of patients with HIV-1 infection and syphilis or neurosyphilis.
Tsai HC; Ye SY; Kunin CM; Lee SS; Wann SR; Tai MH; Shi MH; Liu YC; Chen YS
Cytokine; 2011 May; 54(2):109-16. PubMed ID: 21354815
[TBL] [Abstract][Full Text] [Related]
14. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
15. The insulin-like growth factor system and markers of inflammation in adult patients with inflammatory bowel disease.
Eivindson M; Nielsen JN; Grønbaek H; Flyvbjerg A; Hey H
Horm Res; 2005; 64(1):9-15. PubMed ID: 16088202
[TBL] [Abstract][Full Text] [Related]
16. [Changes of serum matrix metalloproteinases-9 and tissue inhibitors of metalloproteinases-9 in coal workers' pneumoconiosis].
Zou JM; Yuan BJ; Wang DM; Li C; Wu JY
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2010 Jan; 28(1):21-4. PubMed ID: 20426972
[TBL] [Abstract][Full Text] [Related]
17. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease.
von Lampe B; Barthel B; Coupland SE; Riecken EO; Rosewicz S
Gut; 2000 Jul; 47(1):63-73. PubMed ID: 10861266
[TBL] [Abstract][Full Text] [Related]
19. The circulating common gamma chain (CD132) in inflammatory bowel disease.
Nielsen OH; Kirman I; Johnson K; Giedlin M; Ciardelli T
Am J Gastroenterol; 1998 Mar; 93(3):323-8. PubMed ID: 9517632
[TBL] [Abstract][Full Text] [Related]
20. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
